reference/34204582

http://rdf.ncbi.nlm.nih.gov/pubchem/reference/34204582

Outgoing Links

Predicate	Object
contentType	Journal Article\|Research Support, Non-U.S. Gov't
endingPage	165
issn	0361-8609 1096-8652
issueIdentifier	1
pageRange	159-165
publicationName	American Journal of Hematology
startingPage	159
hasFundingAgency	http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_a7aad2afdf2479bdab5d471f9391a826 http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_4cab3d117c180042e4a2f590086d8d85 http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_665c6efce5eca061f87bb5cdb2b63a10
bibliographicCitation	Gottlieb DJ, Sutrave G, Jiang W, Avdic S, Street JA, Simms R, Clancy LE, Antonenas V, Gloss BS, Bateman C, Bishop DC, Micklethwaite KP, Blyth E. Combining CD34+ stem cell selection with prophylactic pathogen and leukemia directed T‐cell immunotherapy to simultaneously reduce graft versus host disease, infection, and leukemia recurrence after allogeneic stem cell transplant. American J Hematol. 2022 May 20;98(1):159–65. doi: 10.1002/ajh.26594.
creator	http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_e7cb58ea739b54842558de4769cfd2e9 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_3e72abdaec9c419f21d96ed27ae97d16 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_9b14a564802f0e89df27d24eed8ed035 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_f96db6d4ab07034fbd2b57f27e17e8ed http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_71d6f875d0bc17461594de5d3b5bf7c0 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_f7f25478f4dfb11a16f4555a6f62654c http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0001-5807-1766 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_00cc9bb55dd378d599266fd81fd41e24 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_f9cc9f4268042d77ad644ae5ab91160b http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_0d4a48db2995090211fac6a5299d0dde http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_741734cd7dc29bb1028a5f74caeee1c9 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_ac0c200b46cecf57fb27c2850755afff http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_81b9b1640707b10115a5c66e82c61d66
date	2022-05-20-04:00^^<http://www.w3.org/2001/XMLSchema#date>
identifier	https://pubmed.ncbi.nlm.nih.gov/35560045 https://doi.org/10.1002/ajh.26594
isPartOf	https://portal.issn.org/resource/ISSN/1096-8652 http://rdf.ncbi.nlm.nih.gov/pubchem/journal/422 https://portal.issn.org/resource/ISSN/0361-8609
language	English
source	https://www.crossref.org/ https://pubmed.ncbi.nlm.nih.gov/
title	Combining CD34+ stem cell selection with prophylactic pathogen and leukemia directed T‐cell immunotherapy to simultaneously reduce graft versus host disease, infection, and leukemia recurrence after allogeneic stem cell transplant
hasPrimarySubjectTerm	http://id.nlm.nih.gov/mesh/D006086Q000209 http://id.nlm.nih.gov/mesh/D006086Q000517 http://id.nlm.nih.gov/mesh/D018380 http://id.nlm.nih.gov/mesh/D054198Q000628 http://id.nlm.nih.gov/mesh/D020031Q000150 http://id.nlm.nih.gov/mesh/D020031Q000628
hasSubjectTerm	http://id.nlm.nih.gov/mesh/D033581 http://id.nlm.nih.gov/mesh/D014184 http://id.nlm.nih.gov/mesh/D004854 http://id.nlm.nih.gov/mesh/D007167 http://id.nlm.nih.gov/mesh/D016896 http://id.nlm.nih.gov/mesh/D006801 http://id.nlm.nih.gov/mesh/D013601
discussesAsDerivedByTextMining	http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8607 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7874 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7387 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8167 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7317 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID11043 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_ef3376902b05bdf1d4f2870c2035036b http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_29f84c0d894769b14b36c5f43f54153e http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_1d2c6279569a5e5473d9efe0530fd802 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8300 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID2907 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_68000b5f90a1d5b5b1a93dbb8aa92d3e

Total number of triples: 60.